IN MEMORIAM (Continuedfrom page 28N) therapeutic agents but is best appreciated in the
use of 67Gain management of lymphoma. This was one of the principal areas of Front's …

The role of nuclear medicine continues to change and evolve, but one area where that
evolution has been rapid and successful is the treatment of non-Hodgkin's lymphoma using I …

One of the new and exciting areas in Nuclear Medicine in the past 5 years has been the
novel treatment for lymphoma with radiolabelled antibodies. These new products have …

Positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) is the best
noninvasive imaging technique for to assess response in patients suffering from lymphoma …

Lymphoma: The Need for New Therapies Page 1 Conventional Treatments for Non—Hodgkin’s
Lymphoma: The Need for New Therapies Craig H. Moskowitz Division of'Hemaro/ogy …

Nuclear medicine and non Hodgkin malignant lymphomas; Medecine nucleaire et lymphomes
malins non hodgkiniens (Journal Article) | ETDEWEB home etdeweb img Made available by US …

The value of 67Ga citrate scanning as a transferrin receptor agent was compared in this
study with a 99mTc-labeled anti-CD22 (B-cell) Fab′ fragment (LL2) in patients with low-and …

[en] The compendium, published as volume 125 in the series, is intended to present the
current knowledge and achievements up to the year 1986 regarding the diagnostic …

Nuclear medicine and non Hodgkin malignant lymphomas|INIS IAEA NUCLEUS Sign In Sign
In Register Help 50+ years of INIS International Nuclear Information System International …

LR131 is a novel radioconjugate consisting of B Lymphocyte Stimulator (BLyS) protein, a B
cell maturation factor of the TNF family that binds selectively to immunoglobulin-positive B …